Kaleidex, a leading specialist in advanced medical device development and manufacturing, has announced the acquisition of OxDevice, a precision engineering and manufacturing company based in Abingdon, Oxfordshire. This strategic move marks Kaleidex’s third acquisition and expansion into the rapidly growing neurovascular and endovascular device sectors.
OxDevice’s integrated model, which spans specialist cleanroom assembly, design, prototyping, clinical trial readiness and commercial manufacturing, reduces time-to-market for early-stage companies and simplifies supply chains for OEMs developing next-generation medical technologies. With proprietary expertise in nitinol processing, fibre optics, and Class 7 cleanroom assembly, OxDevice brings capabilities that complement Kaleidex’s existing portfolio and reinforce its commitment to supporting the full product lifecycle of next-generation medical technologies.
“Becoming part of Kaleidex marks an exciting new chapter for us,” commented Duncan Keeble, CEO of OxDevice. “We’re gaining access to the resources, expertise, and network of a larger group, which will enable us to scale faster and explore new growth opportunities. At the same time, we remain focused on delivering the specialist device development and manufacturing excellence that our customers rely on.”
The acquisition reflects Kaleidex’s commitment to building a platform of like-minded, specialist businesses that combine technical leadership with a people-first culture. Every business within the group is chosen for its alignment with Kaleidex’s core values: care, boldness, trust, passion, and ideas. OxDevice marks the third acquisition for Kaleidex, following the successful onboarding of Oracle Precision in March 2025 and Kirkstall Precision Engineering in July 2024, and its first major milestone under the group’s refreshed identity, formerly known as Medical Precision Group.
There are no planned changes to OxDevice’s leadership or team structure. Kaleidex will support OxDevice’s continued growth by investing in commercial resources, operational efficiencies, and cross-selling opportunities within its existing customer base, whilst directors from OxDevice will join the Kaleidex leadership team to help drive the collective growth of the group.
“This acquisition is a testament to our growth strategy and our dedication to advancing medical manufacturing,” said Jon Lynch, CFO of Kaleidex. “By bringing OxDevice’s unique capabilities into our group, we are expanding our offering into high-growth adjacent markets while significantly enhancing our ability to support OEMs and start-ups with complex device development. Together, we are better positioned to meet the evolving needs of our customers with a broader range of technologies and end-to-end lifecycle support.”
